AI assistant
Sending…
Lyell Immunopharma, Inc. — Director's Dealing 2022
Oct 3, 2022
33362_dirs_2022-10-03_4a820e4d-be9d-4ec0-93e2-205bb6579ec3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2022-09-28
Reporting Person: Thompson Rahsaan (Chief Legal Officer)
More from Lyell Immunopharma, Inc.
Annual Report
2026
Apr 24
Regulatory Filings
2026
Apr 3
Director's Dealing
2026
Feb 12
Director's Dealing
2026
Feb 12
Director's Dealing
2026
Feb 12
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 11